Lenalidomide improves H₂O₂-induced PC12 cell injury by blocking the Notch signaling pathway

ZHENG LV¹, SHAO YIN¹, ZIGUAN CHENG¹ and KEKAI WANG²

¹Department of Orthopedics; ²Anorectal Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610032, P.R. China

Received July 22, 2021; Accepted October 27, 2021

DOI: 10.3892/etm.2022.11348

Abstract. Lenalidomide (LEN) has been reported to exert antitumor, anti-inflammatory, anti-angiogenic and immunomodulatory activities. However, the effects of LEN in spinal cord injury (SCI) are yet to be fully elucidated. The present study was conducted to identify whether LEN has a healing effect on SCI and to determine the underlying mechanism of action. The viability of H₂O₂-stimulated PC12 cells was detected using a Cell Counting Kit-8 assay. The viability of PC12 cells treated with LEN was examined with an MTT assay. The level of lactate dehydrogenase (LDH) was measured using an LDH assay kit, while the levels of the oxidative stress-related factors malondialdehyde, superoxide dismutase, glutathione peroxidase and catalase in PC12 cells were determined using commercial kits. Oxidative stress-related proteins were examined via western blotting. The results of the present study demonstrated that H₂O₂ decreased PC12 cell viability in a dose-dependent manner. However, treatment with LEN significantly improved the viability of H₂O₂-stimulated PC12 cells and alleviated H₂O₂-induced cytotoxic injury. Additionally, LEN treatment inhibited the oxidative stress and apoptosis induced by H₂O₂ in PC12 cells. LEN also improved the motor behavior defect caused by the striatum and ameliorates dopaminergic fiber loss. In summary, it was demonstrated that LEN alleviated the H₂O₂-induced injury of PC12 cells by blocking the Notch signaling pathway, suggesting the value of applying LEN to the treatment of SCI.

Introduction

Spinal cord injury (SCI) is a common and destructive injury caused by external forces. SCI refers to fracture and/or severe complications following dislocation of the spinal cord (1). SCI is known to be mostly caused by road traffic accidents, falls and sports-related accidents, and could further lead to sensory disturbance, motor dysfunction and lower extremity paralysis (2-4). As a result of the unremitting efforts made by global researchers and the successful translation into clinical practice, recovery from SCI through rehabilitation therapies and orthopedic appliances is now possible for mild cases, whereas patients with severe cases continue to risk disability and even death (5,6). Surgical techniques, biological therapies such as stem cell and precursor cell transplantation, and pharmacological therapies such as methylprednisolone (MP) and gangliosides have been approved for the treatment of SCI; however, clinically significant effects have not been reported (7,8). Thus, there is an extremely urgent need to find new therapies for SCI and secondary injury following SCI.

Lenalidomide (LEN), chemically known as (RS)-3-(4-amino-1-oxoisindol-2-yl)piperidine-2,6-dione (molecular formula, C₁₃H₁₃N₃O₃), exerts antitumor, anti-inflammatory, anti-angiogenic and immunomodulatory effects (9,10). LEN also improves the motor behavior defect caused by the striatum and ameliorates dopaminergic fiber loss. This protective effect is accompanied by an decrease in microgliosis in the striatum and hippocampus and reduction in NF-κB activity in Parkinson’s disease (11). LEN has also shown other protective potential, such as exerting anti-inflammatory and neuroprotective effects in a G93A mutant superoxide dismutase (SOD)-1 mouse model of amyotrophic lateral sclerosis (12). The anti-inflammatory effect of LEN is exerted via the regulation of cytokine production by human myeloid-derived primary dendritic cells, which allows for beneficial immunoregulation and is therefore facilitative for treating inflammation-related diseases, including multiple myeloma (MM) (13). LEN inhibits the downstream genes of Notch2 signaling transduction, including recombination signal binding protein for immunoglobulin κ J region (also called CSL or CBF1) and hes family bHLH transcription factor 1 (HES1). Under LEN treatment, Notch2 signaling combines with the expression of multiple drug-resistance proteins to modulate the inhibitory effect on cancer cell proliferation (14).
A previous study reported a significant decline in the expression levels of Notch signaling molecules, including the receptors, the ligands and the downstream cytokines, after treatment with LEN in mesenchymal stem cells (MSCs) from patients with MM (MM-MSCs). It was concluded that treatment with LEN inactivated Notch signaling to restore the osteogenic differentiation of MM-MSCs (15). These previous studies have collectively confirmed the interaction between LEN and Notch signaling, which may play a role in the clinical treatment for SCI.

The present study aimed to verify this hypothesis and the results may contribute to the exploration of the therapeutic potentials of LEN other than for treating MM.

Materials and methods

Cell culture and treatment. The rat adrenal pheochromocytoma cell line, PC12, acquired from the American Type Culture Collection (ATCC), was cultured in ATCC-formulated RPMI-1640 medium (cat. no. 30-2001) supplemented with 10% heat-inactivated horse serum and 5% FBS (all Gibco; Thermo Fisher Scientific, Inc.) in an environment of 95% air and 5% CO₂ at 37°C. The cells were pretreated for 24 h with LEN (cat. no. EY0006; AMQUAR Corporation) dissolved in DMSO of 1.25, 2.5, 5 and 10 µM. H₂O₂ (Shanghai Aladdin Biochemical Technology Co., Ltd.) at a dose 20 µl CCK-8 solution was added to each well and incubated with the cells for 4 h. A microplate reader (RT-3001; Thermo Fisher Scientific, Inc.) was used to measure the absorbance at a wavelength of 490 nm using a universal microplate spectrophotometer.

Cell Counting Kit-8 (CCK-8) assay. The viability of H₂O₂-stimulated PC12 cells was detected using a CCK-8 Cell Proliferation and Cytotoxicity assay (Beijing Solarbio Science & Technology Co., Ltd.). In total, 100 µl cell suspension was added to a 96-well plate at a density of 5x10³ cells/well and precultured in an incubator at 37°C in 5% CO₂. Subsequently, 10 µl CCK-8 solution was added to each well and incubated with the cells for 4 h. A microplate reader (RT-3001; Thermo Fisher Scientific, Inc.) was used to measure the absorbance at a wavelength of 450 nm.

MTT assay. PC12 cells in the logarithmic growth phase were collected, and 100 µl cell suspension was added to a 96-well plate at a density of 5x10³ cells/well. The cells were treated with a concentration gradient of LEN after the formation of the cell monolayer on the bottom of the well. Following 48 h of incubation with LEN in 5% CO₂ at 37°C, 20 µl MTT solution (Procell Life Science & Technology Co., Ltd.) was added to each well and the incubation was continued for 4 h. The incubation was then terminated, and the culture medium was discarded before the addition of 150 µl DMSO to each well. The plate was vibrated using a shaking bed for 10 min at low speed to fully dissolve the crystalized substances. The optical density was measured at a wavelength of 490 nm using a universal microplate spectrophotometer.

Lactate dehydrogenase (LDH) cytotoxicity assay. Cell cytotoxicity was measured by an LDH kit (cat. no. A020-1-2; Nanjing Jiancheng Bioengineering Institute) according to the manufacturer's protocols. Briefly, the H₂O₂-stimulated cells were seeded into a 96-well plate at a density of 1x10⁴ cells/well and received the appropriate treatments of incubation with LEN at doses of 1.25, 2.5, 5 and 10 µM for 24 h at 37°C. Next, the cell culture media was collected and the LDH activity was measured at 530 nm using a microplate reader (Benchmark; Bio-Rad Laboratories, Inc.).

Determination of oxidative stress level. Oxidative stress in PC12 cells was reflected by the levels of malondialdehyde (MDA), SOD, glutathione peroxidase (GSH-Px) and catalase (CAT), as detected using a Lipid Peroxidation MDA Assay kit (cat. no. S0131S; Beyotime Institute of Biotechnology), a SOD Activity Assay kit (cat. no. ab65354; Abcam), GSH-Px Assay kit (cat. no. EKC39116; BioVision, Inc.) and a CAT Assay kit Without Hydrogen Peroxide (cat. no. 700910; Cayman Chemical Company), respectively. All operational procedures followed the manufacturer's protocols.

Western blot analysis. Total protein was extracted from PC12 cells using RIPA lysis buffer (Absin Bioscience, Inc.). The protein concentration was determined using a BCA kit (Beyotime Institute of Biotechnology). Complete denaturation of the samples was performed by incubating the protein in boiling water for 5 min. After electrophoresis using 10% SDS-PAGE (Beijing Solarbio Science & Technology Co., Ltd.), the protein samples (30 µg per lane) were transferred to a PVDF membrane (Corning, Inc.). Subsequently, 5% skimmed milk (Absin Bioscience, Inc.) was used to block the membrane for 2 h at 25°C, followed by incubation with primary antibodies targeting NADPH oxidase (Nox2) (1:5,000; cat. no. ab129068; Abcam), Nox4 (1:1,000; cat. no. ab133303; Abcam), Bcl-2 (1:1,000; cat. no. ab196495; Abcam), Bax (1:1,000; cat. no. 2772; Cell Signaling Technology, Inc.), caspase-3 (1:1,000; cat. no. 9662; Cell Signaling Technology, Inc.), cleaved caspase-3 (1:1,000; cat. no. 9661; Cell Signaling Technology, Inc.), caspase-9 (1:1,000; cat. no. 184786; Abcam), cleaved caspase-9 (1:1,000; cat. no. ab2324; Abcam), Notch2 (1:1,000; cat. no. 5732; Cell Signaling Technology, Inc.), HES-related family bHLH transcription factor with YRPW motif 1 (Hey1; 1:1,000; cat. no. ab154077; Abcam), HES1 (1:1,000; cat. no. ab1988; Cell Signaling Technology, Inc.) and GAPDH (1:1,000; cat. no. ab8245; Abcam) at 4°C overnight. After the membrane was washed with 0.5% TBST, it was incubated with horseradish peroxidase-labeled secondary antibodies [goat anti-rabbit IgG (1:2,000; cat. no. 7074) or horse anti-mouse IgG (1:2,000; cat. no. 7076); both Cell Signaling Technology, Inc.] at room temperature for 1 h. An ECL kit (Beyotime Institute of Biotechnology) was used to visualize the protein bands and ImageJ software (v6; National Institutes of Health) was used to analyze the protein bands.

TUNEL assay. A colorimetric TUNEL Apoptosis Assay kit (cat. no. C1088; Beyotime Institute of Biotechnology) was utilized to observe PC12 cell apoptosis. The cells (5x10⁴/well) seeded into a 24-well plate were fixed with 4% paraformaldehyde (Shanghai Macklin Biochemical Co., Ltd.) at room temperature for 30 min, and incubated with Enhanced Immunostaining Permeabilization Buffer (Beyotime Institute
of Biotechnology) at room temperature for 5 min. After incubation with 0.3% H$_2$O$_2$ in PBS (Sigma-Aldrich; Merck KGaA) at room temperature for 20 min, 50 µl biotin-dUTP was added to label the samples for 1 h at 37˚C in the dark. To develop the colors, the samples were then incubated with 50 µl streptavidin-HRP for 30 min at 37˚C, followed by incubation in 0.5 ml DAB solution for another 30 min at 37˚C and the anti-fluorescence quencher was added dropwise for mounting. The coloration was observed microscopically from three random fields of view using a fluorescence microscope (magnification, x200; Olympus Corporation).

Statistical analysis. The data were analyzed and graphs were generated using GraphPad Prism 6 software (GraphPad Software, Inc.). Data are presented as the mean ± SD. Differences among multiple groups were analyzed using one-way ANOVA with a post hoc Bonferroni multiple comparison test. P<0.05 was considered to indicate a statistically significant difference. All experiments were performed in triplicate.

Results

LEN increases the viability of H$_2$O$_2$-stimulated PC12 cells. The SCI model was established by treating PC12 cells with H$_2$O$_2$. The viability of PC12 cells showed a declining trend as the dose of H$_2$O$_2$ was increased from 100 to 400 µM (Fig. 1A). According to a previous experiment (16), 300 µM was selected as the final dose of H$_2$O$_2$ for the SCI model in view of the appropriate degree of cell death under this dose. Additionally, the viability of PC12 cells treated with different doses of LEN revealed no significant difference compared with the control group (Fig. 1B), indicating the non-cytotoxicity of LEN. After pre-treatment with increasing doses of LEN, the viability of H$_2$O$_2$-stimulated PC12 cells was noticeably improved (Fig. 1C). In addition, the level of LDH in H$_2$O$_2$-stimulated PC12 cells was notably decreased by LEN in a dose-dependent manner (Fig. 1D). Thus, these results indicated that treatment with LEN could revitalize H$_2$O$_2$-stimulated PC12 cells.

LEN inhibits the oxidative stress level in H$_2$O$_2$-stimulated PC12 cells. By examining the production of MDA, SOD, GSH-Px and CAT, the present study investigated the effect of LEN on H$_2$O$_2$-induced oxidative stress in PC12 cells. It was identified that, while H$_2$O$_2$ induced an increased production of MDA, this was notably decreased after pre-treatment with LEN in PC12 cells (Fig. 2A). Conversely, H$_2$O$_2$-induced suppression of SOD, GSH-Px and CAT production was attenuated in a dose-dependent manner by LEN (Fig. 2B-D). Furthermore, the oxidative stress-related proteins, Nox2 and Nox4, were examined and both were revealed to be upregulated under H$_2$O$_2$ stimulation, but downregulated by LEN treatment (Fig. 2E). These results suggested an inhibitory effect of LEN on H$_2$O$_2$-induced oxidative stress in PC12 cells.

LEN extenuates the apoptosis of H$_2$O$_2$-stimulated PC12 cells. H$_2$O$_2$-induced PC12 cell apoptosis was detected in the absence
and presence of pre-treatment with LEN. The results of the TUNEL assay demonstrated a notable increase in the number of apoptotic cells (green fluorescence) in the H\textsubscript{2}O\textsubscript{2} group, but this was significantly decreased by pre-treatment with LEN (Fig. 3A and B). The expression levels of apoptosis-related proteins in PC12 cells were also detected (Fig. 3C), among
which the expression level of anti-apoptotic protein Bcl-2 was decreased by H$_2$O$_2$ and dose-dependently increased after LEN treatment, while Bax, cleaved caspase-3 and cleaved caspase-9 expression exhibited the opposite trend. These results indicated a suppressive effect of LEN on H$_2$O$_2$-induced PC12 cell apoptosis.

LEN blocks the Notch signaling pathway in H$_2$O$_2$-stimulated PC12 cells. Whether LEN interacts with the Notch signaling pathway was preliminarily examined by detecting related protein expression levels in H$_2$O$_2$-stimulated PC12 cells. It was identified that the expression levels of Notch2, Hey1 and HES1 were all significantly increased in H$_2$O$_2$-stimulated PC12 cells, but were gradually decreased along with the increasing doses of LEN (Fig. 4). These findings suggested that treatment with LEN may block the expression of the Notch signaling pathway in H$_2$O$_2$-stimulated PC12 cells.

LEN inhibits H$_2$O$_2$-induced oxidative stress and apoptosis of PC12 cells by blocking the Notch signaling pathway. To verify the involvement of Notch in the action mechanism of LEN, rescue experiments were conducted by pre-treating the cells with the Notch agonist Jagged-1 (JAG) peptide at a concentration of 50 µg/ml, as previously described (17). In addition, 10 µM LEN was chosen for these subsequent procedures. As revealed in Fig. 5A, the level of MDA formerly downregulated by LEN in H$_2$O$_2$-stimulated PC12 cells was significantly upregulated by treatment with JAG. In addition, the levels of SOD, GSH-Px and CAT in LEN-treated H$_2$O$_2$-stimulated PC12 cells were significantly upregulated by treatment with JAG. In addition, the levels of SOD, GSH-Px and CAT in LEN-treated H$_2$O$_2$-stimulated PC12 cells were significantly decreased by JAG (Fig. 5B-D). The expression levels of oxidative stress-related proteins in LEN-treated H$_2$O$_2$-stimulated PC12 cells were also rescued after pre-treatment with JAG, as both Nox2 and Nox4 exhibited re-upregulation (Fig. 5E). Similarly, reduced apoptosis of H$_2$O$_2$-stimulated PC12 cells by LEN was promoted after treatment with JAG (Fig. 5F and G), evidenced by the downregulation of Bcl-2 expression and the upregulation of Bax, cleaved caspase-3 and cleaved caspase-9 expression (Fig. 5H and I). Collectively, these results demonstrated that the Notch agonist could reverse the effects of LEN on the H$_2$O$_2$-induced oxidative stress and apoptosis of PC12 cells.

Figure 3. Effects of LEN on the apoptosis of H$_2$O$_2$-stimulated PC12 cells. (A and B) The apoptosis of H$_2$O$_2$-stimulated PC12 cells in the presence and absence of LEN at different doses, detected by TUNEL (magnification, x200). (C) Relative protein expression of apoptosis-related Bax, Bcl-2, cleaved caspase-3 and cleaved caspase-9 in H$_2$O$_2$-stimulated PC12 cells in the presence and absence of LEN at different doses, detected by western blotting. *P<0.05, **P<0.01 and ***P<0.001 vs. control; #P<0.05, ##P<0.01 and ###P<0.001 vs. H$_2$O$_2$. LEN, lenalidomide.
Discussion

The incidence of SCI has been continuously increasing with the world's economic development, which will not only bring serious physical and psychological harm to the patients themselves, but also result in significant financial burden to society (4,18). Hence, the prevention and treatment of SCI have become major issues in the medical field. In the present study, H$_2$O$_2$ was chosen for the modeling of SCI, considering its wide use in SCI models in previous studies (19,20), and the significantly decreased viability in H$_2$O$_2$-treated PC12 cells was confirmed.

LEN is a Food and Drug Administration-approved drug that has immunomodulatory, antitumor and anti-angiogenic activities, and is commonly used for the treatment of MM and myelodysplastic syndrome (21,22). However, little is known regarding the impact of LEN on other diseases, including SCI. PC12 cells pre-treated with LEN in the present study showed no indication of cytotoxicity, and their viability was significantly improved following stimulation with H$_2$O$_2$, compared with that in cells without LEN pre-treatment. The LDH level, reflecting cytotoxic injury, in H$_2$O$_2$-stimulated PC12 cells was also reduced by LEN. It was therefore suggested that LEN treatment benefits the survival of PC12 cells under the stimulation of H$_2$O$_2$.

Previous studies have reported that an elevated oxidative stress level characterizes the occurrence of SCI and is considered to be a treatment target, with the overproduction of free radicals and lipid peroxidation found in damaged spinal neurons (23,24). LEN has been revealed to have a regulatory effect on inflammatory cytokines as well as certain stress signals (25,26). In addition, it has been reported that combined treatment with LEN and nanoceria produces a suppressive effect in vivo on central nervous system autoimmunity-induced inflammation and oxidative stress (27). In the present study, increased MDA and decreased SOD, GSH-Px and CAT production were observed in H$_2$O$_2$-stimulated PC12 cells. Pre-treatment with LEN effectively inhibited the production of MDA, while promoting that of the anti-oxidants SOD, GSH-Px and CAT. Consistently, the gene expression levels of the reactive oxygen species, Nox2 and Nox4, were comparatively higher in H$_2$O$_2$-stimulated PC12 cells in the absence of LEN and were significantly downregulated in the presence of LEN. These results suggested an anti-oxidative stress role of LEN in the model of SCI.

Inflammation and apoptosis occur in the secondary injury phase that follows the primary mechanical injury in SCI, further resulting in the dysfunction or damage of the central nervous system (28,29). Qu et al (30) revealed that LEN could restrict the formation of osteoclasts and protect osteocytes from IL-1β-induced apoptosis in a mouse model of osteoarthritis. The present study observed a significantly increased number of apoptotic PC12 cells after treatment with H$_2$O$_2$, in addition to the downregulation of anti-apoptotic Bcl-2 protein.

Figure 4. Effects of LEN on the Notch signaling pathway in H$_2$O$_2$-stimulated PC12 cells. Relative protein expression of Notch signaling pathway-related Notch2, Hey1 and HES1 in H$_2$O$_2$-stimulated PC12 cells in the presence and absence of LEN at different doses, detected by western blot analysis. *P<0.05 and ***P<0.001 vs. control; ###P<0.001 vs. H$_2$O$_2$. LEN, lenalidomide; Hey1, HES-related family bHLH transcription factor with YRPW motif 1; HES1, hes family bHLH transcription factor 1.
Figure 5. LEN suppresses $\text{H}_2\text{O}_2$-induced oxidative stress and apoptosis of PC12 cells by blocking the Notch signaling pathway. The production of (A) MDA, (B) SOD, (C) GSH-Px and (D) CAT in $\text{H}_2\text{O}_2$-stimulated PC12 cells treated with LEN in the presence or absence of Notch agonist JAG, detected by corresponding commercial kits. (E) Relative protein expression of Nox2 and Nox4 in $\text{H}_2\text{O}_2$-stimulated PC12 cells treated with LEN in the presence or absence of Notch agonist JAG, detected by western blotting. (F and G) The apoptosis of $\text{H}_2\text{O}_2$-stimulated PC12 cells treated with LEN in the presence or absence of Notch agonist JAG, detected by TUNEL (magnification, x200). (H and I) Relative protein expression of Bax, Bcl-2, cleaved caspase-3 and cleaved caspase-9 in $\text{H}_2\text{O}_2$-stimulated PC12 cells treated with LEN in the presence or absence of Notch agonist JAG, detected by western blotting. *P<0.01 and **P<0.001 vs. control; #P<0.05, ##P<0.01 and ###P<0.001 vs. $\text{H}_2\text{O}_2$; ∆P<0.05, ∆∆P<0.01 vs. LEN + $\text{H}_2\text{O}_2$ and ∆∆∆P<0.001 vs. LEN + $\text{H}_2\text{O}_2$. LEN, lenalidomide; MDA, malondialdehyde; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; CAT, catalase; Nox, NADPH oxidase; JAG, Jagged-1.
expression and upregulation of the pro-apoptotic proteins Bax, cleaved caspase-3 and cleaved caspase-9. However, pre-treatment with LEN decreased the number of apoptotic cells and the expression levels of pro-apoptotic proteins, while increasing the expression of Bcl-2. An anti-apoptotic effect of LEN on H2O2-stimulated PC12 cells was thus demonstrated in the present study.

The present study also investigated the effects of LEN by examining the underlying mechanism. Previous studies determined the role of the interaction between LEN and Notch signaling in inhibiting human gastric cancer cell proliferation and promoting osteogenic differentiation in MM (14,15). Additionally, Cai et al (31) identified that Notch inhibition in vivo by microRNA-139-5p upregulation could potentially attenuate the oxidative stress-induced liver injury in a diabetic model. Notch is also known as an essential regulatory signaling pathway in the process of cellular apoptosis in cerebrovascular diseases (32). More importantly, Notch expression is likely to be inhibited by resveratrol to facilitate the recovery from SCI, according to a recent review (33). In addition, a previous study revealed that circular RNA_0005075 knockdown could alleviate neuropathic pain by inactivating the Notch2 signaling pathway (34). It was observed in the present study that the expression levels of Notch-related proteins, Notch2, Hey1 and HES1, were notably increased in H2O2-stimulated PC12 cells, but were significantly decreased by LEN treatment in a dose-dependent manner. This result preliminarily validated the interaction of LEN and the Notch signaling pathway. The present study further investigated the role of Notch in the effects of LEN by introducing the Notch agonist JAG to H2O2-stimulated PC12 cells pre-treated with LEN. It was revealed that the formerly induced oxidative stress level and mitigated apoptosis caused by LEN treatment were significantly promoted again by Notch activation. This suggested that LEN inhibits the H2O2-induced oxidative stress and apoptosis of PC12 cells by blocking the Notch signaling pathway.

In conclusion, the present study demonstrated that LEN has the ability to alleviate PC12 cell injury induced by H2O2 stimulation, likely by blocking the Notch signaling pathway, revealing the value of LEN in restoring the viability of spinal cord neurons following SCI.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

ZL and KW designed the study, and drafted and revised the manuscript. SY and ZC analyzed the data and searched the literature. All authors performed the experiments. All authors read and approved the final manuscript. ZL and SY confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Eckert MJ and Martin MJ: Trauma: Spinal cord injury. Surg Clin North Am 97: 1031-1045, 2017.
2. Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, Patel A, Plata M and Del Popolo G: Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol 36: 1517-1527, 2018.
3. Witt CD and Fehlings MG: Acute spinal cord injury. J Spinal Disord Tech 28: 202-210, 2015.
4. Kumar R, Lim J, Mekary RA, Rattani A, Dewan MC, Sharif SY, Osorio-Fonseca E and Park KB: Traumatic spinal injury: Global epidemiology and worldwide volume. World Neurosurg 113: e345-e363, 2018.
5. Kjell J and Olson L: Rat models of spinal cord injury: From pathology to potential therapies. Dis Model Mech 9: 1125-1137, 2016.
6. Fan Q, Cavis O, Xiong L and Xia Y: Spinal cord injury: How could acupuncture help? J Acupuncture Meridian Stud 11: 124-132, 2018.
7. Varma AK, Das A, Wallace G IV, Barry J, Vertegel AA, Ray SK and Banik NL: Spinal cord injury: A review of current therapy, future treatments, and basic science frontiers. Neurochem Res 38: 895-905, 2013.
8. Cristante AF, Filho TE, Marcon RM, Letaif OB and Rocha ID: Therapeutic approaches for spinal cord injury. Clinics (Sao Paulo) 67: 1219-1224, 2012.
9. Ravikumar K and Sridhar B: Lenalidomide, an antineoplastic drug, and its hemihydrate. Acta Crystallogr C 65: o502-o505, 2009.
10. Weisel K and Kanz L: Lenalidomide. Recent Results Cancer Res 201: 347-357, 2014.
11. Valera E, Mante M, Anderson S, Rockenstein E and Masliah E: Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation 12: 93, 2015.
12. Mosley RL and Gendelman HE: Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol 222: 1-5, 2010.
13. Yamamoto K, Kitawaki T, Sugimoto N, Fujita H, Kawase Y, Takaori-Kondo A and Kadowaki N: Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide. Immunol Lett 211: 41-48, 2019.
14. Ding W, Zeng T, Tao W, Ge W, Deng V, Lei H, Xiao Y and Liao F: Effect of lenalidomide on the human gastric cancer cell line SGC7901/vincristine notch signaling. J Cancer Res Ther 14: S237-S242, 2018.
15. Guo J, Fei C, Zhao Y, Zhao S, Zheng Q, Su J, Wu D, Li X and Chang C: Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating notch signaling pathway. Oncotarget 8: 55405-55421, 2017.
16. Yi G, Liu L, Lv C, Wei Y and Yan T: Ginsenoside RglI defenses PC-12cells against hydrogen peroxide-caused damage via up-regulation of miR-216a-5p. Life Sci 236: 116948, 2019.
17. Wen F, Hong HK, Tay CY, Yu H, Li H, Yu T, Tijore A, Boey FY, Venkatraman SS and Tan LP: Induction of myogenic differentiation of human mesenchymal stem cells cultured on notch agonist (Jagged-1) modified biodegradable scaffold surface. ACS Appl Mater Interfaces 6: 1652-1661, 2014.
18. Yue JK, Chan AK, Winkler EA, Upadhyayula PS, Readdy WJ and Dhall SS: A review and update on the guidelines for the acute management of cervical spinal cord injury-part II. J Neurosurg Sci 60: 367-384, 2016.

19. Siriphorn A, Chompoopong S and Floyd CL: 17β-estradiol protects Schwann cells against H2O2-induced cytotoxicity and increases transplanted Schwann cell survival in a cervical hemi-contusion spinal cord injury model. J Neurochem 115: 864-872, 2010.

20. Li X, Zhan J, Hou Y, Hou Y, Chen S, Luo D, Luan J, Wang L and Lin D: Coenzyme Q10 regulation of apoptosis and oxidative stress in H2O2 induced BMSC death by modulating the Nrf-2/NQO-1 signaling pathway and its application in a model of spinal cord injury. Oxid Med Cell Longev 2019: 6493081, 2019.

21. Talati C, Sallman D and List A: Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Semin Hematol 54: 159-166, 2017.

22. Flowers CR, Leonard JP and Fowler NH: Lenalidomide in follicular lymphoma. Blood 135: 2133-2136, 2020.

23. Jia Z, Zhu H, Li J, Wang X, Misra H and Li Y: Oxidative stress in spinal cord injury and antioxidant-based intervention. Spinal Cord 50: 264-274, 2012.

24. Hall ED: Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 8: 152-167, 2011.

25. Zhu X, Jiang S, Hu N, Luo F, Dong H, Kang YM, Jones KR, Zou Y, Xiong L and Ren J: Tumour necrosis factor-alpha inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice. Clin Exp Pharmacol Physiol 41: 489-501, 2014.

26. Li L, Hua Y, Dong M, Li Q, Smith DT, Yuan M, Jones KR and Ren J: Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice. Obesity (Silver Spring) 20: 2174-2185, 2012.

27. Eitan E, Hutchison ER, Greig NH, Tweedie D, Celik H, Ghosh S, Fishbein KW, Spencer RG, Sasaki CY, Ghosh P, et al: Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Exp Neurol 273: 151-160, 2015.

28. Zhang N, Yin Y, Xu SJ, Wu YP and Chen WS: Inflammation & apoptosis in spinal cord injury. Indian J Med Res 135: 287-296, 2012.

29. Keane RW, Davis AR and Dietrich WD: Inflammatory and apoptotic signaling after spinal cord injury. J Neurotrauma 23: 335-344, 2006.

30. Qu X, Mei J, Yu Z, Zhai Z, Qiao H and Dai K: Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/ NF-kappaB/RANKL signaling. Biochem Biophys Res Commun 501: 547-555, 2018.

31. Cai Z, Zhao B, Deng Y, Shangguan S, Zhou F, Zhou W, Li X, Li Y and Chen G: Notch signaling in cerebrovascular diseases (Review). Mol Med Rep 14: 2883-2898, 2016.

32. Wei H, Huang L, Wei F, Li G, Huang B, Li J and Cao C: 2020. Up-regulation of miR-139-5p protects diabetic mice from liver tissue damage and oxidative stress through inhibiting notch signaling pathway. Acta Biochim Biophys Sin (Shanghai) 52: 390-400, 2016.

33. Zhang S, Botchway BOA, Zhang Y and Liu X: Resveratrol can inhibit notch signaling pathway to improve spinal cord injury. Ann Anat 223: 100-107, 2019.

34. Zhang Y, Gao T, Li X, Wen CC, Yan XT, Peng C and Xiao Y: Circ_0005075 targeting miR-151a-3p promotes neuropathic pain in CCI rats via inducing NOTCH2 expression. Gene 767: 145079, 2021.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.